ALABX
Price
$12.46
Change
+$0.07 (+0.56%)
Updated
Jan 17 closing price
Net Assets
12.84M
RLEFX
Price
$34.97
Change
+$0.22 (+0.63%)
Updated
Jan 17 closing price
Net Assets
240.18B
Ad is loading...

ALABX vs RLEFX

Header iconALABX vs RLEFX Comparison
Open Charts ALABX vs RLEFXBanner chart's image
ALPS/Smith Balanced Opportunity A
Price$12.46
Change+$0.07 (+0.56%)
VolumeN/A
Net Assets12.84M
American Funds American Balanced R5E
Price$34.97
Change+$0.22 (+0.63%)
VolumeN/A
Net Assets240.18B
ALABX vs RLEFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ALABX vs. RLEFX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALABX is a Buy and RLEFX is a Buy.

Ad is loading...
FUNDAMENTALS
Fundamentals
RLEFX has more cash in the bank: 240B vs. ALABX (12.8M). RLEFX pays higher dividends than ALABX: RLEFX (2.42) vs ALABX (1.55). ALABX was incepted earlier than RLEFX: ALABX (4 years) vs RLEFX (9 years). RLEFX is a more actively managed with annual turnover of: 171.00 vs. ALABX (74.00). RLEFX has a lower initial minimum investment than ALABX: RLEFX (250) vs ALABX (2500). RLEFX annual gain was more profitable for investors over the last year : 12.49 vs. ALABX (8.42).
ALABXRLEFXALABX / RLEFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence4 years9 years-
Gain YTD1.9641.953101%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets12.8M240B0%
Annual Yield % from dividends1.552.4264%
Returns for 1 year8.4212.4967%
Returns for 3 years8.6512.8168%
Returns for 5 yearsN/A30.88-
Returns for 10 years18.10N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GREE1.910.18
+10.40%
Greenidge Generation Holdings
ADEA12.920.16
+1.25%
Adeia
RDVT35.450.41
+1.17%
Red Violet
EFX262.87-1.37
-0.52%
Equifax
AXSM91.93-1.75
-1.87%
Axsome Therapeutics